OEM-TACE: A new therapeutic approach in unresectable intrahepatic cholangiocarcinoma

CardioVascular and Interventional Radiology

Volumn 32, Issue 6, 2009, Pages 1187-1192

  Poggi, Guido ^a   Amatu, A ^a   Montagna, B ^a   Quaretti, P ^b   Minoia, C ^a   Sottani, C ^a   Villani, L ^a   Tagliaferri, B ^a   Sottotetti, F ^a   Rossi, O ^a   Pozzi, E ^a   Zappoli, F ^b   Riccardi, A ^c   Bernardo, G ^a  

^a IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Intrahepatic cholangiocarcinoma; Palliative treatments; Transarterial chemoembolization

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; MICROSPHERE; OXALIPLATIN;

ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOEMBOLIZATION; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSIVE CRISIS; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MICROSPHERES; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 71449087263     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-009-9694-4     Document Type: Article

References (25)

1. Y Shaib HB El-Serag 2004 The epidemiology of cholangiocarcinoma Semin Liver Dis 24 115 125 10.1055/s-2004-828889 15192785 (Pubitemid 38738341)
2. A Nakeeb HA Pitt TA Sohn J Coleman RA Abrams S Piantadosi RH Hruban KD Lillemoe CJ Yeo JL Cameron 1996 Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors Ann Surg 224 463 473 10.1097/00000658-199610000- 00005 1:STN:280:DyaK2s%2FhtVyiug%3D%3D 8857851 (Pubitemid 26337555)
3. K Burak P Angulo TM Pasha K Egan J Petz KD Lindor 2004 Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis Am J Gastroenterol 99 523 526 10.1111/j.1572-0241.2004.04067.x 15056096 (Pubitemid 38524134)
4. EP Berthiaume J Wands 2004 The molecular pathogenesis of cholangiocarcinoma Semin Liver Dis 24 127 137 10.1055/s-2004-828890 1:CAS:528:DC%2BD2cXlvVensbc%3D 15192786 (Pubitemid 38738342)
5. JC Tan NG Coburn NN Baxter A Kiss CH Law 2008 Surgical management of intrahepatic cholangiocarcinoma-a population-based study Ann Surg Oncol 15 600 608 10.1245/s10434-007-9627-x 17987347
6. YH Shaib JA Davila L Henderson KA McGlynn HB El-Serag 2007 Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the United States: a population-based study J Clin Gastroenterol 41 911 917 10.1097/MCG. 0b013e31802f3132 18090160 (Pubitemid 350307078)
7. WR Jarnagin Y Fong, et al. 2001 Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma Ann Surg 234 4 507 519 10.1097/00000658-200110000-00010 1:STN:280:DC%2BD3MrisFCqtA%3D%3D 11573044 (Pubitemid 32946713)
8. SR Alberts GJ Gores GP Kim LR Roberts ML Kendrick CB Rosen ST Chari JA Martenson 2007 Treatment options for hepatobiliary and pancreatic cancer Mayo Clin Proc 82 628 637 10.4065/82.5.628 17493429
9. JM Llovet MI Real X Montana, et al. 2002 Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 1734 1739 10.1016/S0140-6736(02)08649-X 12049862 (Pubitemid 34607087)
10. CM Lo H Ngan WK Tso, et al. 2001 Randomized controlled trial of transarterial lipiodol chemoembolization for hepatocellular carcinoma: Is there room for a new studies? Clin Gastroenterol 32 383 389 10.1097/00004836- 200105000-00005 (Pubitemid 32378268)
11. C Cammà F Schepis A Orlando M Albanese L Shahied F Trevisani P Andreone A Craxì M Cottone 2002 Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 47 54 10.1148/radiol.2241011262 12091661
12. AL Lewis RR Taylor H Brenda, et al. 2006 Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization J Vasc Interv Radiol 17 1335 1343 16923981
13. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
14. A Trotti AD Colevas A Setser V Rusch D Jaques V Budach C Langer B Murphy R Cumberlin CN Coleman P Rubin 2003 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176 181 10.1016/S1053-4296(03)00031-6 12903007 (Pubitemid 36962641)
15. EL Kaplan P Meier 1958 Non parametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
16. R Development Core Team (2005) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org
17. I Endo M Gonen AC Yopp, et al. 2008 Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection Ann Surg 248 84 96 10.1097/SLA.0b013e318176c4d3 18580211
18. N Yonemoto J Furuse T Okusaka K Yamao A Funakoshi S Ohkawa N Boku K Tanaka M Nagase H Saisho T Sato 2007 A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer Jpn J Clin Oncol 37 843 851 10.1093/jjco/hym116 17942578 (Pubitemid 350259003)
19. C Charoentum S Thongprasert B Chewaskulyong S Munprakan 2007 Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma World J Gastroenterol 13 2852 2854 1:CAS:528: DC%2BD2sXot1antrY%3D 17569122
20. B Paule MO Herelle E Rage M Ducreux R Adam C Guettier MP Bralet 2007 Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas Oncology 72 105 110 10.1159/000111117 1:CAS:528:DC%2BD2sXhtlyksLrF 18025804 (Pubitemid 350249137)
21. G Poggi P Quaretti C Minoia, et al. 2008 Transhepatic arterial chemoembolization with oxaliplatin-eluting microsphere (OEM-TACE) for unresectable hepatic tumors Anticancer Res 28 3835 3842 1:CAS:528: DC%2BD1MXht1Whu7w%3D 19192637
22. I Burger K Hong R Schulick C Georgiades P Thuluvath M Choti I Kamel JF Geschwind 2005 Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution J Vasc Interv Radiol 16 353 361 15758131
23. C Aliberti G Benea M Tilli G Fiorentini 2008 Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results CardioVasc Interv Radiol 5 883 888 10.1007/s00270-008-9336-2
24. N Tanaka K Yamakado A Nakatsuka A Fujii K Matsumura K Takeda 2002 Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience Eur J Radiol 41 42 48 10.1016/S0720-048X(01)00414-4 11750151 (Pubitemid 34002989)
25. TJ Vogl W Schwarz K Eichler K Hochmuth R Hammerstingl U Jacob A Scheller S Zangos M Heller 2006 Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy J Cancer Res Clin Oncol 132 745 755 10.1007/s00432-006-0138-0 1:CAS:528:DC%2BD28XptVajsLg%3D 16858591 (Pubitemid 44337935)